PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27497027-3	2016	Zevalin( ) (ibritumomab tiuxetan) is a radioactive drug product, which is the combination of a beta-emitting isotope, (90)Y, linked to the anti-CD20 monoclonal antibody (mAb), rituximab.	ibritumomab tiuxetan	12-32	keratin 20	Homo sapiens	144-148
26025778-0	2015	p53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan.	ibritumomab tiuxetan	59-79	transformation related protein 53, pseudogene	Mus musculus	0-3
25705531-0	2015	Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.	ibritumomab tiuxetan	124-144	PML nuclear body scaffold	Homo sapiens	19-22
25677780-2	2015	(90)Y ibritumomab tiuxetan ((90)Y-IT), an anti-CD20 radionuclide-conjugated antibody, has demonstrated clinical efficacy in DLBCL with a favorable toxicity profile.	ibritumomab tiuxetan	6-26	keratin 20	Homo sapiens	47-51
25395425-0	2015	Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.	ibritumomab tiuxetan	0-11	DNA damage inducible transcript 3	Homo sapiens	44-48
25705531-4	2015	We report the case of a 66-year-old woman who developed PML a year after completion of therapy with rituximab, ibritumomab, and bendamustine.	ibritumomab tiuxetan	111-122	PML nuclear body scaffold	Homo sapiens	56-59
25440606-2	2014	Two products targeting the CD20 antigen are approved in the treatment of non-Hodgkin B-cell lymphoma (NHBL): iodine 131-tositumomab and yttrium 90-ibritumomab tiuxetan.	ibritumomab tiuxetan	136-167	keratin 20	Homo sapiens	27-31
25596049-7	2014	Ibritumomab tiuxetan (Zevalin) is an anti-CD20 mouse monoclonal antibody labeled with Yttrium-90 (Y-90).	ibritumomab tiuxetan	0-20	keratin 20	Homo sapiens	42-46
23875170-3	2013	Today, two products targeting the CD20 antigen are approved: (131)I-tositumomab (Bexxar( )), and (90)Y-ibritumomab tiuxetan (Zevalin( )).	ibritumomab tiuxetan	103-123	keratin 20	Homo sapiens	34-38
25379535-2	2014	In a clinical field, two successful examples of this treatment protocol are currently extended by (90)Y-ibritumomab tiuxetan (Zevalin) and (131)I-tositumomab (Bexxar), both of which are anti-CD20 monoclonal antibodies coupled to cytotoxic radioisotopes and are approved for the treatment of non-Hodgkin lymphoma patients.	ibritumomab tiuxetan	104-124	keratin 20	Homo sapiens	191-195
21571787-1	2011	UNLABELLED: Targeted radioimmunotherapy with (90)Y-labeled ibritumomab tiuxetan is a novel therapeutic approach for CD20-positive relapsed or refractory non-Hodgkin lymphoma (NHL).	ibritumomab tiuxetan	59-79	keratin 20	Homo sapiens	116-120
23049552-0	2012	RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution.	ibritumomab tiuxetan	13-33	Ras like without CAAX 1	Homo sapiens	0-3
22628300-1	2012	To exploit the B-lymphocyte antigen-CD20 binding capacity of the Ibritumomab tiuxetan (IBTN) monoclonal antibody (mAb) for imaging, the over-expression of B cells in non-Hodgkin"s lymphoma (NHL) (a myeloproliferative disorder of the lymphatic system) was investigated.	ibritumomab tiuxetan	65-85	membrane spanning 4-domains A1	Homo sapiens	15-40
22628300-1	2012	To exploit the B-lymphocyte antigen-CD20 binding capacity of the Ibritumomab tiuxetan (IBTN) monoclonal antibody (mAb) for imaging, the over-expression of B cells in non-Hodgkin"s lymphoma (NHL) (a myeloproliferative disorder of the lymphatic system) was investigated.	ibritumomab tiuxetan	87-91	membrane spanning 4-domains A1	Homo sapiens	15-40
21034409-10	2010	Ibritumomab Tiuxetan and Tositumomab are murine anti-CD20 monoclonal antibodies, not chimeric antibodies.	ibritumomab tiuxetan	0-20	keratin 20	Homo sapiens	53-57
21575926-0	2011	(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma.	ibritumomab tiuxetan	6-26	keratin 20	Homo sapiens	165-169
21210565-4	2004	Because of its specific presence on non-Hodgkin lymphoma tumor cells, the antigen is a therapeutic target of different anti-CD20 Abs, such as rituximab for monotherapy or combination therapy with a chemotherapeutic agent, or tositumomab ((131)I-labeled) or ibritumomab ((90)Y-conjugated) for radioimmunotherapy (RIT), all of which are approved by the United States Food and Drug Administration for the treatment of this disease (4).	ibritumomab tiuxetan	257-268	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	124-128
19858392-0	2009	Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.	ibritumomab tiuxetan	64-95	BCL2 apoptosis regulator	Homo sapiens	30-35
20542986-1	2010	PURPOSE: This study aimed to evaluate the efficacy and safety of the treatment with (90)Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL).	ibritumomab tiuxetan	90-110	DNA damage inducible transcript 3	Homo sapiens	208-212
20542986-5	2010	Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after (90)Y-ibritumomab tiuxetan administration.	ibritumomab tiuxetan	128-139	DNA damage inducible transcript 3	Homo sapiens	79-83
19858392-0	2009	Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.	ibritumomab tiuxetan	64-95	immunoglobulin heavy locus	Homo sapiens	36-39
19427037-2	2009	The success of anti-CD20 antibody drugs such as Rituximab, Ibritumomab, and Tositumomab has promoted the development of new generation of anti-CD20 antibodies for therapeutic applications.	ibritumomab tiuxetan	59-70	keratin 20	Homo sapiens	20-24
19427037-2	2009	The success of anti-CD20 antibody drugs such as Rituximab, Ibritumomab, and Tositumomab has promoted the development of new generation of anti-CD20 antibodies for therapeutic applications.	ibritumomab tiuxetan	59-70	keratin 20	Homo sapiens	143-147
18773247-0	2009	Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	42-62	keratin 20	Homo sapiens	80-84
19642457-2	2009	90Y ibritumomab tiuxetan (Zevalin) combines the specificity of rituximab for the CD20 antigen and the therapeutic effect of beta irradiation.	ibritumomab tiuxetan	4-24	keratin 20	Homo sapiens	81-85
19819920-2	2009	A number of trials have shown significantly higher response rates and longer progression-free survival times in patients treated with the CD20-targeted radioimmunoconjugate yttrium-90-ibritumomab tiuxetan compared with the standard of care.	ibritumomab tiuxetan	173-204	keratin 20	Homo sapiens	138-142
18927323-2	2008	90Y-ibritumomab is an antibody targeting CD20 receptors on the surface of lymphocytes.	ibritumomab tiuxetan	0-15	keratin 20	Homo sapiens	41-45
19061730-3	2008	This radioimmunotherapeutic agent consists of ibritumomab, a murine anti-CD20 monoclonal antibody, conjugated to the metal chelator tiuxetan for retention of the beta emitter (90)Y.	ibritumomab tiuxetan	46-57	keratin 20	Homo sapiens	73-77
18268399-11	2008	CONCLUSION: Treatment with 90Y ibritumomab tiuxetan induced a clinically relevant CR in a patient with CD20-positive cHL.	ibritumomab tiuxetan	31-51	keratin 20	Homo sapiens	103-107
18194857-2	2008	90Y-ibritumomab tiuxetan is the only therapy approved for use after rituximab failure and is currently indicated in the EU for the treatment of adults with rituximab-relapsed or refractory CD20-positive follicular B-cell NHL.	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	189-193
18268399-12	2008	Thus, we will expand treatment of relapsed CD20-positive HL with 90Y ibritumomab tiuxetan at our institution.	ibritumomab tiuxetan	69-89	keratin 20	Homo sapiens	43-47
16367911-0	2005	Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.	ibritumomab tiuxetan	89-109	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	49-53
20641770-9	2004	Later, ibritumomab (intact murine anti-CD20 MAb), was labeled with (111)In or (90)Y for NHL imaging and therapy (9, 10).	ibritumomab tiuxetan	7-18	keratin 20	Homo sapiens	39-43
20641438-0	2004	(111)In-Ibritumomab tiuxetan (111)In-Ibritumomab tiuxetan ((111)In-2B8) is an immunoconjugate of a murine anti-CD20 monoclonal antibody (MAb) that is chelated to (111)In for imaging of lymphoid malignancies (1-3).	ibritumomab tiuxetan	8-28	membrane spanning 4-domains A1	Homo sapiens	111-115
20641438-0	2004	(111)In-Ibritumomab tiuxetan (111)In-Ibritumomab tiuxetan ((111)In-2B8) is an immunoconjugate of a murine anti-CD20 monoclonal antibody (MAb) that is chelated to (111)In for imaging of lymphoid malignancies (1-3).	ibritumomab tiuxetan	37-57	membrane spanning 4-domains A1	Homo sapiens	111-115
20641438-11	2004	Ibritumomab was developed as an anti-CD20 MAb and was characterized by Reff et al.	ibritumomab tiuxetan	0-11	membrane spanning 4-domains A1	Homo sapiens	37-41
17323056-1	2007	BACKGROUND: In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	61-81	keratin 20	Homo sapiens	177-181
17287964-5	2007	An example for this is the anti-CD20 antibody ibritumomab tiuxetan, which is coupled to 90Yttrium and shows comparable activity to rituximab.	ibritumomab tiuxetan	46-66	keratin 20	Homo sapiens	32-36
16826593-1	2006	Radioimmunotherapy (RIT) with Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) combines the tumor targeting attributes of a monoclonal antibody against the CD20 antigen and the pure beta-radiation of 90Y.	ibritumomab tiuxetan	47-67	keratin 20	Homo sapiens	155-159
17087138-2	2006	90Y-ibritumomab tiuxetan is a monoclonal antibody directed against the CD20 antigen to which a radioactive isotope of yttrium is attached, used for treating follicular lymphomas (FL).	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	71-75
16690521-1	2006	Yttrium 90 ((90)Y) ibritumomab tiuxetan (Zevalin), a radiolabeled monoclonal antibody against the CD20 antigen, is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin"s lymphoma (NHL), including patients with rituximab-refractory follicular NHL.	ibritumomab tiuxetan	41-48	membrane spanning 4-domains A1	Homo sapiens	98-110
16321828-2	2006	Especially the commercially available anti-CD20 antibody 90Y-ibritumomab tiuxetan is currently under investigation in various trials including dose escalation and autologous hematopoietic progenitor cell support.	ibritumomab tiuxetan	57-81	keratin 20	Homo sapiens	43-47
16540013-3	2006	90Y-ibritumomab tiuxetan utilizes a monoclonal anti-CD20 antibody to deliver beta-emitting yttrium-90 to the malignant B-cells.	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	52-56
17886241-3	2007	Zevalin is a commercially available variation of the murine anti-CD20 antibody ibritumomab coupled to Yttrium 90 via the tiuxetan chelator.	ibritumomab tiuxetan	79-90	keratin 20	Homo sapiens	65-69
17396483-1	2007	Tositumomab/iodine-131 tositumomab (Bexxar) and ibritumomab tiuxetan (Zevalin) are radioimmunoconjugates targeting the CD20 antigen.	ibritumomab tiuxetan	48-68	keratin 20	Homo sapiens	119-123
16979437-3	2006	In clinical trials, (90)Y ibritumomab tiuxetan has produced rates of response as high as 83% in patients with relapsed or refractory CD20+ NHL.	ibritumomab tiuxetan	26-46	keratin 20	Homo sapiens	133-137
16979439-3	2006	Y-90 ibritumomab tiuxetan (Zevalin) and I-131 tositumomab (Bexxar) both recognize the CD-20 surface antigen found on normal and malignant B cells.	ibritumomab tiuxetan	5-25	keratin 20	Homo sapiens	86-91
16203814-1	2005	PURPOSE: Targeted radioimmunotherapy with yttrium-90 (90Y)-labeled ibritumomab tiuxetan (Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of relapsed or refractory CD20+ non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	67-87	keratin 20	Homo sapiens	200-204
15802280-4	2005	(90)Y-Ibritumomab tiuxetan (Zevalin); Schering AG, Berlin, Germany), the first RIT approved for use in relapsed/refractory indolent NHL, comprises the murine anti-CD20 monoclonal antibody ibritumomab, covalently linked to the high-energy beta-emitter, yttrium-90, by the chelator, tiuxetan.	ibritumomab tiuxetan	6-17	keratin 20	Homo sapiens	163-167
16091197-4	2005	Other studies in indolent NHL suggest that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease and have potential utility as part of initial treatment as well.	ibritumomab tiuxetan	113-133	keratin 20	Homo sapiens	61-65
16111589-1	2005	PURPOSE: To evaluate two potential approaches to predicting site-specific patterns of recurrence after yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) for CD20+ B-cell Non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	114-134	keratin 20	Homo sapiens	164-168
16207072-3	2005	This radioimmunoconjugate consists of the monoclonal IgG1 antibody ibritumomab (the murine parent of rituximab) bound to the chelator tiuxetan and linked by a stable thiourea covalent bond to the beta-emitting radionuclide 90Y.	ibritumomab tiuxetan	67-78	LOC105243590	Mus musculus	53-57
15786024-6	2005	90Y-ibritumomab tiuxetan comprises the murine IgG1 anti-CD20 antibody ibritumomab, covalently linked to the beta-emitter 90 Y by a chelator tiuxetan.	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	56-60
15786026-3	2005	Two anti-CD20 RIT agents have now been approved for the treatment of refractory NHL: 90Y-ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, San Diego, CA, and Schering AG, Berlin, Germany) is approved in both the United States and Europe, and 131I-tositumomab (Bexxar; Corixa Corp, Seattle, WA) is approved only in the United States.	ibritumomab tiuxetan	85-109	keratin 20	Homo sapiens	9-13
15844660-4	2004	The radioimmunoconjugate 90Y-ibritumomab tiuxetan is directed against the B-cell antigen, CD20.	ibritumomab tiuxetan	25-49	keratin 20	Homo sapiens	90-94
16304400-7	2005	Other studies in NHL have clearly demonstrated that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease, and have potential utility as part of initial treatment as well.	ibritumomab tiuxetan	122-142	keratin 20	Homo sapiens	70-74
15016644-0	2004	Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.	ibritumomab tiuxetan	24-44	keratin 20	Homo sapiens	68-72
15498146-1	2004	Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation.	ibritumomab tiuxetan	58-78	keratin 20	Homo sapiens	190-194
15342663-10	2004	In addition, a phase I study of a radiolabeled anti-CD20 antibody (ibritumomab tiuxetan) was completed in 2003, and a phase II study for indolent B-NHL will be initiated.	ibritumomab tiuxetan	67-87	keratin 20	Homo sapiens	52-56
15016644-1	2004	We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20(+), B-cell, non-Hodgkin lymphoma (NHL).	ibritumomab tiuxetan	50-70	keratin 20	Homo sapiens	156-160
14710396-8	2003	This is a conjugate of an anti-CD20 mAb (ibritumomab, the murine parent of rituximab) with the beta-emitter radionuclide (90)Y.	ibritumomab tiuxetan	41-52	membrane-spanning 4-domains, subfamily A, member 1	Mus musculus	31-35
15045033-1	2004	This article will review the clinical development of ibritumomab tiuxetan, a yttrium-90-conjugated monoclonal antibody to CD20, for patients with relapsed B-cell non-Hodgkin"s lymphomas.	ibritumomab tiuxetan	53-73	keratin 20	Homo sapiens	122-126
15045033-2	2004	Ibritumomab is the murine parent anti-CD20 antibody that was engineered to make the human chimeric antibody rituximab.	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	38-42
15023434-1	2004	Anti-CD20 antibodies radiolabeled with I-131 tositumomab (Bexxar) or Y-90-Ibritumomab tiuxetan (Zevalin), are similarly efficacious in treating chemotherapy-refractory non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	69-94	keratin 20	Homo sapiens	5-9
14529425-6	2003	Radioimmunotherapy with the rituximab and ibritumomab tiuxetan (Zevalin) regimen was recently approved for the treatment of relapsed or refractory low-grade, follicular or CD20+ transformed NHL, including rituximab refractory follicular NHL.	ibritumomab tiuxetan	42-62	keratin 20	Homo sapiens	172-176
12837157-3	2003	Upon relapse 3 years later, the patient was treated again with radioimmunotherapy consisting of 90Y-ibritumomab tiuxetan anti-CD20 monoclonal antibody, with a good response and acceptable bone marrow suppression.	ibritumomab tiuxetan	96-120	keratin 20	Homo sapiens	126-130
12837157-0	2003	Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin"s lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.	ibritumomab tiuxetan	7-27	keratin 20	Homo sapiens	33-37
15154741-2	2003	90Y-ibritumomab tiuxetan consists of the anti-CD20 monoclonal antibody (MAb) ibritumomab covalently linked to tiuxetan for chelation of 90Y for therapy.	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	46-50
12837157-0	2003	Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin"s lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.	ibritumomab tiuxetan	7-27	CD22 molecule	Homo sapiens	143-147
12837157-1	2003	Ibritumomab tiuxetan is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy-refractory CD20+ B-cell non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	0-20	keratin 20	Homo sapiens	130-134
16224429-7	2003	This study indicates that immune-based therapies such as rituximab and ibritumomab-tiuxetan (anti-CD20) and epratuzumab (anti-CD22) are feasible in pediatric cases of mature B-cell NHLs.	ibritumomab tiuxetan	71-91	keratin 20	Homo sapiens	98-102
12663713-1	2003	PURPOSE: Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a high rate of tumor response in patients with relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin"s lymphoma (NHL).	ibritumomab tiuxetan	92-112	keratin 20	Homo sapiens	71-75
12621016-1	2003	UNLABELLED: Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates (111)In for imaging or dosimetry and (90)Y for radioimmunotherapy (RIT).	ibritumomab tiuxetan	12-32	keratin 20	Homo sapiens	44-48
12621016-1	2003	UNLABELLED: Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates (111)In for imaging or dosimetry and (90)Y for radioimmunotherapy (RIT).	ibritumomab tiuxetan	88-99	keratin 20	Homo sapiens	44-48
15154742-2	2003	90Y-ibritumomab tiuxetan was the first RIT to be approved for the treatment of relapsed and refractory B-cell non-Hodgkin"s lymphoma (NHL), and consists of the anti-CD20 murine monoclonal antibody, ibritumomab, covalently bound to the linker tiuxetan, which securely chelates the radioactive isotope 90Y.	ibritumomab tiuxetan	4-24	keratin 20	Homo sapiens	165-169
15154742-2	2003	90Y-ibritumomab tiuxetan was the first RIT to be approved for the treatment of relapsed and refractory B-cell non-Hodgkin"s lymphoma (NHL), and consists of the anti-CD20 murine monoclonal antibody, ibritumomab, covalently bound to the linker tiuxetan, which securely chelates the radioactive isotope 90Y.	ibritumomab tiuxetan	4-15	keratin 20	Homo sapiens	165-169
12074764-7	2002	Ibritumomab is the murine anti-CD20 antibody that was engineered to develop the human chimeric antibody rituximab.	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	31-35
12468399-6	2002	The radioconjugated anti-CD20 mAbs ibritumomab tiuxetan and I131-tositumomab also have impressive clinical activity in low-grade B-cell NHL, and the former has demonstrated superior CR rates to rituximab.	ibritumomab tiuxetan	35-55	keratin 20	Homo sapiens	25-29
11762415-0	2001	Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	38-58	keratin 20	Homo sapiens	32-36
11877765-1	2002	BACKGROUND: Zevalin consists of a murine anti-CD20 monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates indium-111 ((111)In) for imaging and dosimetry and yttrium-90 ((90)Y) for radioimmunotherapy (RIT).	ibritumomab tiuxetan	72-83	keratin 20	Homo sapiens	46-50
11850494-1	2002	90Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic agent recently approved for the treatment of relapsed or refractory low-grade, follicular, or CD20+ transformed non-Hodgkin"s lymphoma (NHL).	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	153-157
11762415-1	2001	Zevalin (ibritumomab tiuxetan, IDEC-Y2B8) is a murine IgG1 kappa monoclonal antibody conjugated to tiuxetan (MXDTPA) that chelates Yttrium or Indium and is directed against the CD 20 molecules of B lymphocytes.	ibritumomab tiuxetan	9-29	keratin 20	Homo sapiens	177-182
11587375-2	2001	Ibritumomab is the murine parent anti-CD20 antibody engineered to make the human chimeric antibody rituximab.	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	38-42
11226003-3	2000	Ibritumomab is the murine parent anti-CD20 antibody that is linked through a MX-DTPA chelator to yttrium 90 (90Y) to form the radioimmunoconjugate 90Y-ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA).	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	38-42
11226003-3	2000	Ibritumomab is the murine parent anti-CD20 antibody that is linked through a MX-DTPA chelator to yttrium 90 (90Y) to form the radioimmunoconjugate 90Y-ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA).	ibritumomab tiuxetan	147-171	keratin 20	Homo sapiens	38-42
34227176-4	2021	Ibritumomab tiuxetan radioimmunotherapy (RIT) is a radioimmunoconjugate of anti-CD20 monoclonal antibody linked to chelator tiuxetan and radioisotope.	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	80-84
10541376-7	1999	The Ibritumomab antibody targets the CD20 antigen.	ibritumomab tiuxetan	4-15	keratin 20	Homo sapiens	37-41
34204102-1	2021	PURPOSE: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin"s lymphoma using the theranostic pair of 111In and 90Y anti-CD20 ibritumomab tiuxetan (Zevalin ) at myeloablative radiation-absorbed doses with autologous stem cell support.	ibritumomab tiuxetan	264-271	keratin 20	Homo sapiens	237-241
35158894-2	2022	The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan.	ibritumomab tiuxetan	134-145	keratin 20	Homo sapiens	76-80